NCT00633997View on ClinicalTrials.gov

Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

December 31, 2008

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Vildagliptin

50 mg orally twice daily for 10 days (last dose morning of day 10)

DRUG

Vildagliptin

Trial Locations (1)

21225

Novartis Investigator Site, Baltimore

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY